Evidence map›Paper›PMID 39421711›Full record

ArticleContemporary oncology (Poznan, Poland)2024

The antitumour efficacy of hesperidin vs. cisplatin against non-small lung cancer cells A549 and H460

Sherine M Ibrahim, Maryam S Sayed, Dina M Abo-Elmatty, Noha M Mesbah, Asmaa R Abdel-Hamed

Abstract read
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sherine M IbrahimDepartment of Biochemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza, Egypt.
Maryam S SayedDepartment of Biochemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza, Egypt.
Dina M Abo-ElmattyDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Noha M MesbahDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Asmaa R Abdel-HamedDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung cancer is the most common type of cancer, causing worldwide mortality. Therefore, this study is necessary for continuing research into new effective and safe treatments. Recently, herbal medicines have been used for the treatment of various diseases such as cancer. This study aimed to investigate the potential anti-proliferative activity and investigate the mechanisms of hesperidin extract on the non-small lung cancer cells A549 and H460 vs. cisplatin Material and methods: To determine the cytotoxic effects of the hesperidin extract on non-small lung cancer cells, sulphorhdamine B assay was performed. To show the inhibition of migration by hesperidin extract, wound healing assay was conducted. A quantitative polymerase chain reaction test was used to quantify the expressions of Results: The hesperidin extract could significantly inhibit proliferation of non-small lung cancer cells A549 and H460. Western blot assay demonstrated that hesperidin induced suppression of nuclear factor κB signalling pathway. The messenger RNA expression levels of Conclusions: Our study demonstrated that hesperidin extract could significantly inhibit non-small lung cancer cell growth by induction of the apoptosis signalling pathway. Therefore, hesperidin might open novel strategies for effective and safe cancer treatment and reduce the adverse side effects of several chemotherapeutic treatments such as cisplatin.

Indexed as

apoptosiscisplatinhesperidinMiR-34aNF-κBnon-small cell lung cancerPDL-1

Identifiers

PMID39421711
PMCPMC11480907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.